clinical trial · NCT05700448
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Extranodal NK/T-cell LymphomaSugemalimabPlaceboPegaspargaseGemcitabineOxaliplatin
brief summary
The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.
started
Jun 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2029
last updated
Feb 5, 2026
official title
A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol